Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM

Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine , Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low‐den...

Full description

Saved in:
Bibliographic Details
Published in:EMBO molecular medicine 2021-09, Vol.13 (9), p.e14789-n/a
Main Authors: Tsui, Hoyee, Han, Su Ji, van Rooij, Eva
Format: Article
Language:English
Subjects:
Arrhythmia
Cardiac arrhythmia
Cardiomyopathy
CD36 antigen
Cholesterol
Coronary artery disease
Disease
EMBO04
Genotype & phenotype
Heart
Heart diseases
Lipids
Lipoproteins
Mutation
News & Views
Oxidative stress
Peroxisome proliferator-activated receptors
Risk factors
Views
Young adults
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine , Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low‐density lipoproteins (oxLDL) and ACM disease penetrance, which contributes to fibro‐fatty cardiac remodeling via the oxLDL/CD36/PPARγ axis. These data identify oxidized low‐density lipoproteins as a risk factor for ACM and uncover a novel therapeutic intervention option to block disease pathogenesis. Graphical Abstract E. van Rooij & colleagues discuss the study by Sommariva et al , in this issue of EMBO Mol Med , that identifies a positive correlation between oxLDL circulating levels and ACM disease penetrance, and uncovers a novel therapeutic intervention option to block disease pathogenesis.
ISSN:1757-4676
1757-4684
DOI:10.15252/emmm.202114789